AU612168B2 - Novel process for purification of hepatitis a virions - Google Patents

Novel process for purification of hepatitis a virions Download PDF

Info

Publication number
AU612168B2
AU612168B2 AU20518/88A AU2051888A AU612168B2 AU 612168 B2 AU612168 B2 AU 612168B2 AU 20518/88 A AU20518/88 A AU 20518/88A AU 2051888 A AU2051888 A AU 2051888A AU 612168 B2 AU612168 B2 AU 612168B2
Authority
AU
Australia
Prior art keywords
hav
aqueous phase
cells
extracting
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU20518/88A
Other languages
English (en)
Other versions
AU2051888A (en
Inventor
Marcy E. Armstrong
Emilio A. Emini
John A. Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2051888A publication Critical patent/AU2051888A/en
Application granted granted Critical
Publication of AU612168B2 publication Critical patent/AU612168B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Physical Water Treatments (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Non-Flushing Toilets (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU20518/88A 1987-08-06 1988-08-05 Novel process for purification of hepatitis a virions Expired AU612168B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8272087A 1987-08-06 1987-08-06
US082720 1987-08-06

Publications (2)

Publication Number Publication Date
AU2051888A AU2051888A (en) 1989-03-23
AU612168B2 true AU612168B2 (en) 1991-07-04

Family

ID=22173006

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20518/88A Expired AU612168B2 (en) 1987-08-06 1988-08-05 Novel process for purification of hepatitis a virions

Country Status (16)

Country Link
US (1) US5521082A (enExample)
EP (1) EP0302692B1 (enExample)
JP (1) JPH0648980B2 (enExample)
KR (1) KR970001711B1 (enExample)
AT (1) ATE84067T1 (enExample)
AU (1) AU612168B2 (enExample)
CY (1) CY1773A (enExample)
DE (1) DE3877082T2 (enExample)
DK (1) DK173215B1 (enExample)
ES (1) ES2042751T3 (enExample)
GR (1) GR3007158T3 (enExample)
IE (1) IE61294B1 (enExample)
IL (1) IL87257A0 (enExample)
NZ (1) NZ225583A (enExample)
PT (1) PT88178B (enExample)
ZA (1) ZA885726B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637114B2 (en) * 1989-06-14 1993-05-20 University Of Birmingham, The Method of preparing vaccines against rna viruses

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
JPH0834362B2 (ja) * 1991-03-08 1996-03-29 ローム株式会社 電気部品取り外し機
GB9111230D0 (en) * 1991-05-24 1991-07-17 Wellcome Found Virus production
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
PT751988E (pt) * 1994-03-22 2000-05-31 Immune Response Corp Inc Producao e isolamento altamente eficientes de particulas virais
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
KR100762477B1 (ko) * 2001-05-31 2007-10-02 주식회사 포스코 고로의 출선구 개공장치
EP1432791B2 (en) * 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
US20050272029A1 (en) * 2002-08-16 2005-12-08 Bertrand Saunier Hepatitis c viral-like particle purification
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
NZ582495A (en) 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
MY192159A (en) * 2015-10-15 2022-08-03 Biocon Ltd Method for detecting neutralizing antibodies against recombinant human insulin in human serum
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7216091A (enExample) * 1971-12-03 1973-06-05
US3919044A (en) * 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
US3994870A (en) * 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637114B2 (en) * 1989-06-14 1993-05-20 University Of Birmingham, The Method of preparing vaccines against rna viruses

Also Published As

Publication number Publication date
IE882407L (en) 1989-02-06
DK437988A (da) 1989-04-04
DE3877082D1 (de) 1993-02-11
PT88178A (pt) 1989-06-30
IE61294B1 (en) 1994-10-19
US5521082A (en) 1996-05-28
CY1773A (en) 1995-10-20
JPS6451080A (en) 1989-02-27
DK173215B1 (da) 2000-04-03
ATE84067T1 (de) 1993-01-15
PT88178B (pt) 1995-03-01
KR890003407A (ko) 1989-04-14
ES2042751T3 (es) 1993-12-16
EP0302692A3 (en) 1990-02-14
EP0302692A2 (en) 1989-02-08
KR970001711B1 (ko) 1997-02-14
NZ225583A (en) 1991-07-26
DE3877082T2 (de) 1993-06-03
GR3007158T3 (enExample) 1993-07-30
IL87257A0 (en) 1988-12-30
EP0302692B1 (en) 1992-12-30
DK437988D0 (da) 1988-08-05
JPH0648980B2 (ja) 1994-06-29
ZA885726B (en) 1989-04-26
AU2051888A (en) 1989-03-23

Similar Documents

Publication Publication Date Title
AU612168B2 (en) Novel process for purification of hepatitis a virions
AU2020294216B2 (en) Methods of detection and removal of rhabdoviruses from cell lines
CA2197683C (en) Method for preparing an influenza virus, antigens obtained and applications thereof
Kalnciema et al. Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches
KR20180097558A (ko) 지카 바이러스 백신
EP0522291B1 (en) Process for purifying hepatitis a virus (HAV), virus thus purified and vaccine compositions containing it
JPH0748277A (ja) Ａ型肝炎ウィルスワクチン
JP2002517250A (ja) 弱毒化ペスチウイルス
Gilead et al. Characterization of the Tumorlike (T) Antigen Induced by Type 12 Adenovirus: I. Purification of the Antigen from Infected KB Cells and a Hamster Tumor Cell Line
EP0468702A2 (en) Novel process for purification of Hepatitis-A virus capsids
JP6734137B2 (ja) インビトロにおいて生成したウイルスの精製方法及びウイルスのクリアランスアッセイ
CZ324795A3 (en) METHOD OF ISOLATING SURFACE VIRAL HEPATITIS B ANTIGEN CONTAINING preS2 PEPTIDE
US4136168A (en) Process for the preparation of neuraminidase from viral sources and methods of utilizing same
HK32794A (en) Novel process for purification of hepatitis a virions
KR20210061939A (ko) 구제역 바이러스 백신 항원의 순도 증가 방법
CN120700002A (zh) 携带polyUC的重组寨卡病毒及其应用
RO111472B1 (ro) Procedeu de purificare a capsidelor virusului de hepatită A
RU2417262C1 (ru) Штамм "белгородский-03" вируса геморрагической болезни кроликов для изготовления вакцинных и диагностических препаратов
CN113293147A (zh) 一种新型冠状病毒的规模化纯化方法
HU203675B (en) Process for producing sub-unit-vaccine against aujeszky-disease of pigs
CN109943536A (zh) 一种戊型肝炎病毒、培养方法及其灭活疫苗的制备方法
CA2070903A1 (en) Process for purifying hepatitis a virus (hav), virus thus purified and vaccine compositions containing it
HK1227433A1 (en) Methods of detection and removal of rhabdoviruses from cell lines
HK1227433B (en) Methods of detection and removal of rhabdoviruses from cell lines